Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04671251 |
|
Recruitment Status :
Completed
First Posted : December 17, 2020
Last Update Posted : May 4, 2022
|
Sponsor:
Avalo Therapeutics, Inc.
Information provided by (Responsible Party):
Avalo Therapeutics, Inc.
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | March 30, 2022 |
| Actual Study Completion Date : | March 30, 2022 |
| Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
|---|---|---|
| 1 |
September 27, 2022 |